Select Biotech Winners in Advance of ASCO Conference
Source: Ian Cooper, Wealth Daily  (4/20/12)
"Any time a company is expected to present healthy data at ASCO, the speculation over FDA approval, buyout, and game-changing findings can jet stock prices going into the conference." More >

Electrifying Biotechnology: A Shot at Shocking Profits
Source: Patrick Cox, Penny Sleuth  (4/20/12)
"The discovery of reversible electroporation revolutionized biotechnology research. Cracking open a cell's pores allows researchers to get stuff into cells they weren't able to before." More >

Gilead Sciences' Hepatitis Drug in Spotlight
Source: Minyanville, Brett Chase  (4/20/12)
"Both medical and investor communities will scrutinize results from an experimental, next-generation treatment for the liver-destroying virus hepatitis C." More >

Deep Value Found in Small Medtech: Jason Mills
Source: George S. Mack, The Life Sciences Report  (4/19/12)
Medical device companies need to demonstrate four qualities to be good investment ideas, according to Senior Medical Devices Analyst and Managing Director Jason Mills of Canaccord Genuity. In this exclusive interview with The Life Sciences Report, Mills shares his precise criteria and pinpoints specific growth names that are trading at value levels. More >

Five Ways to Play Heart Health
Source: George S. Mack, The Life Sciences Report  (4/19/12)
You almost never hear an analyst say his sector is trading at a significant discount across all market caps. But when I interviewed Senior Analyst and Managing Director Jason Mills of Canaccord Genuity for The Life Sciences Report, that was his evaluation of the cardiovascular space in medtech. A negative environment can certainly create opportunity, and Mills says specific medtech stocks are trading at "trough levels" not seen since the technology meltdown of 2001–2002. More >

Will Illumina Reject Roche's Raised Takeover Bid?
Source: Aabha Rathee, Wall St. Cheat Sheet  (4/17/12)
"Shareholders of the San-Diego based Illumina seem to be collectively siding with their board, which has already rejected two bids from Roche." More >

Superior Biotechnology Leads to Superior Drugs
Source: Ray Blanco, Penny Sleuth  (4/17/12)
"Revolutions in our understanding of the genome and proteome are opening up new pathways toward vanquishing the cancer foe." More >

The Wireless Revolution Hits Medicine
Source: The Wall Street Journal, Ron Winslow  (4/16/12)
"The digital world has been in a separate orbit from our medical cocoon, and it's time the boundaries be taken down." More >

Treating Depression with Electrodes Inside the Brain
Source: CNN Health, Sanjay Gupta and Andy Segal  (4/14/12)
"The procedure, called deep brain stimulation, targets a small brain structure known as Area 25, the 'ringleader' for the brain circuits that control our moods." More >

Junior Resource and Biotech Investing Share Profit Potential
Source: Alex Daley and Doug Hornig, Casey Research  (4/12/12)
Several Casey Research publications focus on the junior resource sector because this is a prime speculative market—one where individual investors can still turn a small amount of money into a fortune, provided they bring the proper tools to the table. Yet resource juniors by no means stand alone. Biotechnology is another good market for speculation. In fact, despite the very different science and economics at work, the biotech and junior resource sectors share some interesting traits. Investors will find a lot to like in both. More >

Vaccine Therapies Hold Promise for Investors: Stephen Dunn
Source: George S. Mack of The Life Sciences Report  (4/12/12)
Developing vaccines to treat and/or prevent disease promises life-changing benefits for patients and unique opportunities for investors. In this interview with The Life Sciences Report, LifeTech Capital Senior Managing Director and President Stephen Dunn discusses the roadblocks encountered by some developers of immune therapies and how other companies are working around those obstacles, producing investment opportunities in the process. More >

Playing the Immune System for Profit
Source: George S. Mack, The Life Sciences Report  (4/12/12)
I had an opportunity to pose some questions once again to Stephen Dunn who is president and senior managing director of research at LifeTech Capital, a division of Aurora Capital, which has a presence in growth hotbeds India and China. LifeTech is one of those boutique investment banks that researches small-cap stocks that need capital and attention. The firm specializes in biotech and medtech, and it really does get an opportunity to get inside little companies to know the people and to understand the science. Dunn gets to do things that he wouldn't get to do in a bulge-bracket banking environment, and after 25 years in his industry he has done nearly everything, including negotiations for intellectual property agreements to product deals, venture capital and mergers and acquisitions. . . More >

Weight Loss Stocks Race to End the Obesity Epidemic
Source: Diane Alter, Money Morning  (4/10/12)
"The economic burden of obesity is estimated to be 10% of total health care costs, with projections continuing to grow as the obesity epidemic spreads. For investors, that means weight loss stocks are poised to gain." More >

Breaking the Mold of Oncology Drug Development
Source: Seeking Alpha, Brian Nichols  (4/10/12)
"Looking at all oncology products on the market, it is striking to note how each targets a single factor in the complex processes that control tumor growth and invasion. It is almost like attempting to stop traffic in a city by blocking a single avenue: It only slows down traffic but doesn't stop it completely." More >

Fatty Acids Fight Cancer Spread
Source: News Medical  (4/9/12)
"Tiny agents found in omega-3 could potentially be used to block the path of primary cancer tumors, preventing the advance to secondary-stage cancers." More >

Nanotechnology Used to Hunt for Hidden Pathogens
Source: ScienceDaily  (4/9/12)
"The new nanoparticle-based technique may be used to detect microbes that have challenged scientists for centuries because they hide deep in human tissue and are able to reprogram cells to successfully evade the immune system." More >

Biotech Stocks: How to Invest in the Buyout Binge
Source: William Patalon, Money Morning  (4/9/12)
"The very same problem that has big pharma execs wringing their hands is also creating one of the biggest profit opportunities we've seen in years." More >

Studies Suggest that When It Comes to Drug Development Success, Size Matters
Source: Alex Philippidis, Genetic Engineering & Biotechnology News  (4/9/12)
"Studies have come to the conclusion that biologics hold better prospects than traditional small molecules of advancing all the way from the lab to the clinic to the market." More >

The Generic Drug Boom
Source: Patrick Cox, The Daily Reckoning  (4/9/12)
"Many popular and profitable medicines are nearing the end of their patent-protection periods. As blockbusters begin to face competition from generics, big pharma stands to lose." More >

Small-Cap Ideas with Double-Digit Growth Potential: Frederick "Rick" Wise
Source: George S. Mack of The Life Sciences Report  (4/5/12)
You can own large medtech and diversified medical supply companies for low volatility and incremental upside in a trending economy (yawn. . .), but small- and mid-cap companies offer the real double-digit growth possibilities. In this exclusive interview with The Life Sciences Report, Analyst and Managing Director Frederick "Rick" Wise of Leerink Swann shares small-cap ideas that could wake up investors' portfolios. More >

Beautiful Music from Small Medtech
Source: George S. Mack of The Life Sciences Report  (4/5/12)
I was already aware that the Manhattan School of Music (MSM) produced the world's greatest musicians, but I didn't know that great sellside analysts were also minted there. Managing Director Frederick "Rick" Wise of New York City-based Leerink Swann is a proud MSM graduate, and he likes to say that he took the "classical route" to Wall Street. "I believe music was great preparation for being an analyst," he says. "I've been deciphering symbols and interpreting them and conveying the bottom line to people on a stage." More >

Antibody Offers Hope Against Cancers
Source: San Francisco Chronicle, Victoria Colliver  (4/3/12)
"In a potential breakthrough for cancer research, Stanford immunologists discovered they can shrink or even get rid of a wide range of human cancers by treating them with a single antibody." More >

Technology Improves Neural Imaging, Human Brain Research
Source: Laboratory Equipment  (4/2/12)
"A new cost-effective neural imaging system allows researchers to make much more complex maps of the brain with just one camera and one imaging system." More >

With or Without "Obamacare," Healthcare Stocks Are Headed Higher
Source: Don Miller, Money Morning  (4/2/12)
"With the bill's fate up in the air, major players will have to devise new strategies for either outcome." More >

Early Third-Party Testing Benefits Medical Devices Producers
Source: Today's Medical Developments, Pam Streed  (4/2/12)
"Early engagement of third-party testing partner yields significant benefits to medical device manufacturers." More >